Do you want to read an article? Please log in or register.
Evaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn's disease using real world data
Inflammatory Bowel Disease
Related content
Early Initiation of Tumor Necrosis Factor Antagonist-based Therapy for Patients with Crohn's Disease Reduces Costs Compared With Late Initiation
Clin Gastroenterol Hepatol.
Beilman CL, Kirwin E, Ma C, McCabe C, Fedorak RN, Halloran B
doi: 10.1016/j.cgh.2018.07.032.
Inflammatory Bowel Disease
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice
Biologicals.
Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T
doi: 10.1016/j.biologicals.
Inflammatory Bowel Disease
Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy
Inflamm Bowel Dis.
Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM
doi: 10.1093/ibd/izz001.
Inflammatory Bowel Disease
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
Gut.
Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR
doi: 10.1136/gutjnl-2019-318256.
Inflammatory Bowel Disease
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review
BMC Gastroenterol.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R
doi: 10.1186/s12876-020-01332-w.
Inflammatory Bowel Disease
Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
J Crohns Colitis.
Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW
doi: 10.1093/ecco-jcc/jjz042.
Inflammatory Bowel DiseaseFurther Publications
Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial
Gut.
de Groof EJ, Stevens TW, Eshuis EJ, Gardenbroek TJ, Bosmans JE, van Dongen JM, Mol B, Buskens CJ, Stokkers PCF, Hart A, D'Haens GR, Bemelman WA, Ponsioen CY, LIR!C study group.
doi: 10.1136/gutjnl-2018-317539.
RECOMMENDED
Inflammatory Bowel Disease
Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Inflamm Bowel Dis.
Hamdeh S, Aziz M, Altayar O, Olyaee M, Murad MH, Hanauer SB
doi: 10.1093/ibd/izaa031.
Inflammatory Bowel DiseaseFurther Publications
Telemonitoring of Crohn's Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis
J Med Internet Res.
Del Hoyo J, Nos P, Bastida G, Faubel R, Muñoz D, Garrido-Marín A, Valero-Pérez E, Bejar-Serrano S, Aguas M
doi: 10.2196/15505.